Clinical trials: Decompensated Cirrhosis
Decompensated Cirrhosis
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions.
- Trial name
- NCT05121870
- Testing
- UC-MSCs, Saline containing 1% Human serum albumin（solution without UC-MSCs）
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing 302 Hospital
Hepatitis B, Decompensated Cirrhosis
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage).
- Trial name
- NCT05086536
- Testing
- no intervention
- Where
- 7 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Decompensated Cirrhosis
CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
The COVID-19 outbreak has exposed many strengths and weaknesses of delivering healthcare, and we want to assess whether patients with advanced liver cirrhosis can be effectively monitored at home, to limit hospital visits and…
- Trial name
- NCT05045924
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Liver Failure, Thrombocytopenia
Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with…
- Conditions
- Liver Failure, Thrombocytopenia, Decompensated Cirrhosis
- Trial name
- NCT04906083
- Testing
- Avatrombopag, Standard medical treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tongji Hospital
Decompensated Cirrhosis
Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.
The current prospective randomized controlled trial would aim to study the efficacy of targeted albumin therapy versus standard medical treatment in reduction in 6-month mortality in recurrent ascites in patients with…
- Trial name
- NCT04679571
- Testing
- Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Alcoholic, Progression
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
A population based incidence cohort will enroll patients newly diagnosed with cirrhosis to investigate disease characteristics and outcomes, explore mechanisms predicting early death and hospital admission, and assess new…
- Conditions
- Liver Cirrhosis, Alcoholic, Progression, Liver Diseases, Decompensated Cirrhosis
- Trial name
- ProDoc (NCT04422223)
- Where
- Denmark
- Volunteers
- 550 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Decompensated Cirrhosis
Effect of Liver MSCs in Blood of Patients With Liver Disease.
Liver MSCs or Adult Derived Human Liver Stem/progenitor Cells (ADHLSCs) infusions are currently being developed as a therapeutic medicinal product for the treatment of different liver defects.
- Trial name
- CIRRHOTIQUE01 (NCT03632148)
- Where
- Belgium
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Decompensated Cirrhosis
Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis
The purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) transplantation in patients with Decompensated Cirrhosis.
- Trial name
- NCT02786017
- Testing
- Conventional therapy, Injectable Collagen Scaffold + HUC-MSCs
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Sciences
Liver Diseases, Liver Fibrosis
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
- Conditions
- Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis
- Trial name
- NCT03479125
- Testing
- Ultrasound
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Conatus Pharmaceuticals Inc.
NASH Related Decompensated Cirrhosis
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
The study will be conducted in the Department of Hepatology, Institute of Liver \& Biliary Sciences, New Delhi. As a part of this study history will be taken and clinical examination will be done.
- Trial name
- NCT02868164
- Testing
- Fecal Microbiota Transplantation, Standard Treatment, Weight Reduction
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis of Liver
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
Cirrhosis of liver is a leading cause of morbidity and mortality worldwide. Complications like ascites, spontaneous bacterial peritonitis, variceal bleed, hepatic encephalopathy, hepatorenal syndrome (HRS) and hepatocellular…
- Trial name
- NCT03911037
- Testing
- G-CSF
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Decompensated Liver Cirrhosis
Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis
Decompensated liver cirrhosis is a life-threatening chronic liver disease with high mortality. Liver transplantation is the only option that can improve the survival of these patients; however, this procedure is associated with…
- Trial name
- NCT03945487
- Testing
- umbilical cord-derived mesenchymal stem cell, Comprehensive treatment
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
Decompensated Cirrhosis
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new…
- Trial name
- ENCORE-LF (NCT03205345)
- Testing
- Emricasan (25 mg), Emricasan (5 mg)
- Where
- 76 sites in United States
- Volunteers
- 210 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Decompensated Cirrhosis, Bleeding Varices
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
The purpose of this study is to determine whether early use of transjugular intrahepatic portosystemic shunt (TIPS) with Polytetrafluoroethylene (PTFE) covered stents is able to prolong the survival in patients with advanced…
- Trial name
- NCT01370161
- Testing
- TIPS treatment, Medical treatment
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Air Force Military Medical University, China
Decompensated Cirrhosis
Management of Decompensated HCV Cirrhotic Patients
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation.
- Trial name
- NCT03547895
- Testing
- Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol), vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Hepatitis C, Chronic, Cirrhosis, Decompensated
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
There are now several licensed drug treatments for patients with HCV infection. These medications have been shown to be very effective in getting rid of the virus in patients with HCV infection including those with early stages…
- Trial name
- NCT02597166
- Testing
- Ledipasvir/Sofosbuvir
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Decompensated Liver Cirrhosis
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
Decompensated liver cirrhosis is one of the life-threatening complication of chronic liver disease. Liver transplantation currently is the only effective method that can improve the survival of these patients.
- Trial name
- NCT03529136
- Testing
- UC-MSC
- Volunteers
- 252 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Decompensated Cirrhosis
To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.
All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016. Decompensated cirrhosis patients will be randomized into Group 1: MVP (Moderate Volume Paracentesis) of less than 5 litres with iv albumin at a dose 8…
- Trial name
- NCT02467322
- Testing
- Albumin, ascitic fluid
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis, Portal Vein Thrombosis
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
Portal vein thrombosis (PVT) refers to an obstruction in the trunk of the portal vein. It can extend downstream to the portal branches, or upstream to the splenic and/or the mesenteric veins.
- Conditions
- Decompensated Cirrhosis, Portal Vein Thrombosis, Bleeding Varices
- Trial name
- NCT01326949
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), ET+NSBB
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Air Force Military Medical University, China